Barry Rosenberg
Managing Director & Senior Partner
Chicago
Barry Rosenberg is a core member of the Health Care, Strategy, and Marketing, Sales & Pricing practices at Boston Consulting Group. He is a member of the firm’s Health Care Scientist Network and serves on BCG’s Career Development Committee.
Since joining BCG in 2006, Barry has focused on advising clients in the medical technology and health care provider sectors. He has been quoted in the New York Times and Wall Street Journal, and published in the Journal of the American Medical Association (JAMA).
Barry is a thought leader in medtech strategy and commercial excellence. In particular, he has supported medtech clients in developing crucial account management, economic selling, and pricing capabilities. He has a deep understanding of the US hospital landscape, including hospital economics, patient outcomes, and the differences among top hospital systems.
Before joining BCG, Barry trained as a resident physician in general surgery at University Hospital of the University of Michigan Health System. He has direct clinical experience managing patients in outpatient, inpatient, emergency room, operating-room, and intensive-care-unit settings.
Here are some facts to clear up the confusion.
A new consumer sentiment survey reveals concrete steps that health care providers can take to accelerate patients’ return.
Barry Rosenberg, BCG managing director and senior partner, discusses the two major challenges currently facing medtech: growth and outcomes.
Understanding how each new test works, what it can and cannot do, and when and under what circumstances it should be used is critical to avoiding confusion and misapplication.
We need better testing to get people treated and then get companies back to work.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
Read more about Surgical Complications and Hospital Finances
Prioritizing R&D spending can reverse the current declines in medtech innovation productivity, but that will require changing the way most medtech companies approach decision making about innovation.
The health care industry is in the midst of sweeping changes. Given high investor expectations and pressure on prices and profit margins, medtech companies must take action.
As US hospital systems consolidate, medtech companies that develop a top-quality KAM function will build a powerful advantage in the near and longer terms.
In Reply The 2 letter writers raise conflicting arguments about the allocation of costs in hospital accounting systems. Dr Weeks argues for allocating more costs, in particular labor, as fixed, whereas Dr Stensland argues for allocating fewer as fixed.